stockrow
Friday 6 November 2026
Export SRRK’s income statement to Excel — free account
Scholar Rock Holding Corporation
SRRK Healthcare Biotechnology
Scholar Rock Holding Corporation’s revenue for fiscal 2022 (year ended December 2022) was $33.2 million.
- EPS
- +14.3%
- Free cash flow
- +8.88%
- Total debt
- +294.3%
Quarter to June 2026, against a year earlier
46.94
1.44
+3.16%
Follow SRRK
Alert me
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(218.04%) | (123.08%) | (138.94%) | (167.77%) | |
| (119.63%) | (85.97%) | (86.70%) | (94.63%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(106.82%) | (114.03%) | (89.42%) | (93.69%) | |
Average Days of Receivables |
— | — | — | — | |
Free Cash Flow per Share |
(2.41) | (2.62) | (2.39) | (2.27) | |
Free Cash Flow |
(274.64) | (300.64) | (303.86) | (297.01) | |
Capital Expenditures |
(0.59) | (0.60) | (0.40) | (0.18) | |
| Other line items | |||||
Cash ROIC |
(38.45%) | (42.18%) | (31.90%) | (31.53%) | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Interest Coverage |
(46.81) | (55.80) | (55.52) | (38.02) | |
Operating CF/Net income |
0.78 | 0.79 | 0.74 | 0.73 | |
Depreciation/Fixed assets |
(1.48) | (1.12) | (0.45) | 0.50 | |
Capex/Depreciation |
0.19 | 0.32 | 0.62 | (0.32) | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(2.41) | (2.62) | (2.38) | (2.27) | |
Capex per Share |
(0.01) | (0.01) | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates · fundamentals updated 25 Oct 2026